{
    "2021-03-21": [
        [
            {
                "time": "2021-Q1",
                "original_text": "【中金医药】2021年一季度业绩预览：核心标的增长强劲，调整是布局良机",
                "features": {
                    "keywords": [
                        "中金医药",
                        "2021年一季度",
                        "核心标的",
                        "增长强劲",
                        "布局良机"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-03-21",
                "original_text": "又一国产PD-1治疗肺癌适应证上市，或惠及超半数肺癌患者",
                "features": {
                    "keywords": [
                        "国产PD-1",
                        "肺癌",
                        "适应证",
                        "上市",
                        "惠及"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-03-21",
                "original_text": "角膜塑形镜利于儿童近视防控，重点推荐欧普康视、昊海生科等【东吴医药朱国广团队|0321周报】",
                "features": {
                    "keywords": [
                        "角膜塑形镜",
                        "儿童近视",
                        "欧普康视",
                        "昊海生科",
                        "东吴医药"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗器械",
                        "眼科"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-WEEKLY",
                "original_text": "医药生物行业周报：基因细胞治疗CDMO黄金赛道有望孕育下一个药明生物",
                "features": {
                    "keywords": [
                        "医药生物",
                        "基因细胞治疗",
                        "CDMO",
                        "黄金赛道",
                        "药明生物"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药",
                        "基因治疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}